Regulatory systems for hypoxia-inducible gene expression in ischemic heart disease gene therapy.
Ischemic heart diseases are caused by narrowed coronary arteries that decrease the blood supply to the myocardium. In the ischemic myocardium, hypoxia-responsive genes are up-regulated by hypoxia-inducible factor-1 (HIF-1). Gene therapy for ischemic heart diseases uses genes encoding angiogenic growth factors and anti-apoptotic proteins as therapeutic genes. These genes increase blood supply into the myocardium by angiogenesis and protect cardiomyocytes from cell death. However, non-specific expression of these genes in normal tissues may be harmful, since growth factors and anti-apoptotic proteins may induce tumor growth. Therefore, tight gene regulation is required to limit gene expression to ischemic tissues, to avoid unwanted side effects. For this purpose, various gene expression strategies have been developed for ischemic-specific gene expression. Transcriptional, post-transcriptional, and post-translational regulatory strategies have been developed and evaluated in ischemic heart disease animal models. The regulatory systems can limit therapeutic gene expression to ischemic tissues and increase the efficiency of gene therapy. In this review, recent progresses in ischemic-specific gene expression systems are presented, and their applications to ischemic heart diseases are discussed.
Department of Bioengineering, College of Engineering, Hanyang University, Seoul 133-791, Republic of Korea.
Hyun Ah
HA
Kim
Taiyoun
T
Rhim
Minhyung
M
Lee
D000818:Animals; D004195:Disease Models, Animal; D005786:Gene Expression Regulation; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D000860:Hypoxia / Q000235:genetics; D051793:Hypoxia-Inducible Factor 1 / Q000235:genetics / Q000378:metabolism; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000628:therapy*
D051793:Hypoxia-Inducible Factor 1